A5086483620- Lung Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Esophageal Cancer Research and Treatment
- Lung Cancer Treatments and Mutations
- Radiation Therapy and Dosimetry
- Radiomics and Machine Learning in Medical Imaging
- Gastric Cancer Management and Outcomes
- Effects of Radiation Exposure
- Medical Imaging Techniques and Applications
- Lung Cancer Research Studies
- Esophageal and GI Pathology
- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Radiation Dose and Imaging
- Cancer Cells and Metastasis
- Occupational and environmental lung diseases
- Cancer survivorship and care
- Radiopharmaceutical Chemistry and Applications
- Inflammatory Biomarkers in Disease Prognosis
- Chemotherapy-induced cardiotoxicity and mitigation
- Pleural and Pulmonary Diseases
- Pancreatic and Hepatic Oncology Research
- Advances in Oncology and Radiotherapy
- Ultrasound and Hyperthermia Applications
The University of Texas MD Anderson Cancer Center
2016-2025
Ministry of Education of the People's Republic of China
2025
Tsinghua University
2024
Ganzhou People's Hospital
2024
Guangdong Provincial People's Hospital
2024
Hangzhou Normal University
2024
Chongqing University
2023
Pfizer (United Kingdom)
2022
Incyte (United States)
2022
Merck (Germany)
2022
Brain metastasis (BM) is a leading cause of death from non-small-cell lung cancer (NSCLC). Reasoning that activation the epidermal growth factor receptor (EGFR) contributes to radiation resistance, we undertook phase II trial EGFR inhibitor erlotinib with whole-brain therapy (WBRT) in an attempt extend survival time for patients BM NSCLC. Additional end points were radiologic response and safety.Eligible had NSCLC, regardless status. Erlotinib was given at 150 mg orally once per day 1 week,...
Radiomics is the use of quantitative imaging features extracted from medical images to characterize tumor pathology or heterogeneity. Features measured at pretreatment have successfully predicted patient outcomes in numerous cancer sites. This project was designed determine whether radiomics non–small cell lung (NSCLC) change during therapy and those (delta-radiomics features) can improve prognostic models. were calculated weekly intra-treatment computed tomography for 107 patients with...
Purpose This randomized trial compared outcomes of passive scattering proton therapy (PSPT) versus intensity-modulated (photon) radiotherapy (IMRT), both with concurrent chemotherapy, for inoperable non–small-cell lung cancer (NSCLC). We hypothesized that PSPT exposes less tissue to radiation than IMRT and thereby reduces toxicity without compromising tumor control. The primary end points were grade ≥ 3 pneumonitis (RP) local failure (LF). Patients Methods Eligible patients had stage IIB...
Circulating tumor DNA (ctDNA) molecular residual disease (MRD) following curative-intent treatment strongly predicts recurrence in multiple types, but whether further can improve outcomes patients with MRD remains unclear. We applied CAPP-Seq ctDNA analysis to 218 samples from 65 receiving chemoradiation therapy (CRT) for locally advanced NSCLC, including 28 consolidation immune checkpoint inhibition (CICI). Patients undetectable after CRT had excellent or not they received CICI. Among such...
Whether dosimetric advantages of proton beam therapy (PBT) translate to improved clinical outcomes compared with intensity-modulated radiation (IMRT) remains unclear. This randomized trial total toxicity burden (TTB) and progression-free survival (PFS) between these modalities for esophageal cancer.This phase IIB randomly assigned patients PBT or IMRT (50.4 Gy), stratified histology, resectability, induction chemotherapy, stage. The prespecified coprimary end points were TTB PFS. TTB, a...
Consensus is lacking as to the optimal radiotherapy dose and fractionation schedule for treating bone metastases.To assess relative efficacy of high-dose, single-fraction stereotactic body (SBRT) vs standard multifraction (MFRT) alleviation pain in patients with mostly nonspine metastases.This prospective, randomized, single-institution phase 2 noninferiority trial conducted at a tertiary cancer care center enrolled 160 radiologically confirmed painful metastases from September 19, 2014,...